162 related articles for article (PubMed ID: 15715457)
1. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist.
Ulven T; Kostenis E
J Med Chem; 2005 Feb; 48(4):897-900. PubMed ID: 15715457
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.
Uller L; Mathiesen JM; Alenmyr L; Korsgren M; Ulven T; Högberg T; Andersson G; Persson CG; Kostenis E
Respir Res; 2007 Feb; 8(1):16. PubMed ID: 17328802
[TBL] [Abstract][Full Text] [Related]
3. Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor.
Ishizuka T; Matsui T; Okamoto Y; Ohta A; Shichijo M
Cardiovasc Drug Rev; 2004; 22(2):71-90. PubMed ID: 15179446
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist ramatroban on allergic rhinitis model in mice.
Suzuki Y; Inoue T; Yamamoto A; Sugimoto Y
Biol Pharm Bull; 2011; 34(4):507-10. PubMed ID: 21467637
[TBL] [Abstract][Full Text] [Related]
5. CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
Sugimoto H; Shichijo M; Okano M; Bacon KB
Eur J Pharmacol; 2005 Nov; 524(1-3):30-7. PubMed ID: 16256979
[TBL] [Abstract][Full Text] [Related]
6. Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.
Robarge MJ; Bom DC; Tumey LN; Varga N; Gleason E; Silver D; Song J; Murphy SM; Ekema G; Doucette C; Hanniford D; Palmer M; Pawlowski G; Danzig J; Loftus M; Hunady K; Sherf BA; Mays RW; Stricker-Krongrad A; Brunden KR; Harrington JJ; Bennani YL
Bioorg Med Chem Lett; 2005 Mar; 15(6):1749-53. PubMed ID: 15745833
[TBL] [Abstract][Full Text] [Related]
7. On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2.
Mathiesen JM; Christopoulos A; Ulven T; Royer JF; Campillo M; Heinemann A; Pardo L; Kostenis E
Mol Pharmacol; 2006 Apr; 69(4):1441-53. PubMed ID: 16418339
[TBL] [Abstract][Full Text] [Related]
8. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.
Ulven T; Receveur JM; Grimstrup M; Rist Ø; Frimurer TM; Gerlach LO; Mathiesen JM; Kostenis E; Uller L; Högberg T
J Med Chem; 2006 Nov; 49(23):6638-41. PubMed ID: 17154491
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives.
Mitsumori S; Tsuri T; Honma T; Hiramatsu Y; Okada T; Hashizume H; Inagaki M; Arimura A; Yasui K; Asanuma F; Kishino J; Ohtani M
J Med Chem; 2003 Jun; 46(12):2436-45. PubMed ID: 12773047
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro evaluation of a selective antagonist and the corresponding radioligand for the prostaglandin D2 receptor CRTH2.
Ulven T; Gallen MJ; Nielsen MC; Merten N; Schmidt C; Mohr K; Tränkle C; Kostenis E
Bioorg Med Chem Lett; 2007 Nov; 17(21):5924-7. PubMed ID: 17845848
[TBL] [Abstract][Full Text] [Related]
11. Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma.
Issahaku AR; Agoni C; Soremekun OS; Kubi PA; Kumi RO; Olotu FA; Soliman MES
Comb Chem High Throughput Screen; 2019; 22(8):521-533. PubMed ID: 31538888
[TBL] [Abstract][Full Text] [Related]
12. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro.
Sugimoto H; Shichijo M; Iino T; Manabe Y; Watanabe A; Shimazaki M; Gantner F; Bacon KB
J Pharmacol Exp Ther; 2003 Apr; 305(1):347-52. PubMed ID: 12649388
[TBL] [Abstract][Full Text] [Related]
13. Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
Sykes DA; Bradley ME; Riddy DM; Willard E; Reilly J; Miah A; Bauer C; Watson SJ; Sandham DA; Dubois G; Charlton SJ
Mol Pharmacol; 2016 May; 89(5):593-605. PubMed ID: 26916831
[TBL] [Abstract][Full Text] [Related]
14. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants.
Gyles SL; Xue L; Townsend ER; Wettey F; Pettipher R
Immunology; 2006 Nov; 119(3):362-8. PubMed ID: 17067313
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2.
Mimura H; Ikemura T; Kotera O; Sawada M; Tashiro S; Fuse E; Ueno K; Manabe H; Ohshima E; Karasawa A; Miyaji H
J Pharmacol Exp Ther; 2005 Jul; 314(1):244-51. PubMed ID: 15798001
[TBL] [Abstract][Full Text] [Related]
16. A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst.
Royer JF; Schratl P; Lorenz S; Kostenis E; Ulven T; Schuligoi R; Peskar BA; Heinemann A
Allergy; 2007 Dec; 62(12):1401-9. PubMed ID: 17714552
[TBL] [Abstract][Full Text] [Related]
17. 3-Indolyl sultams as selective CRTh2 antagonists.
Tumey LN; Robarge MJ; Gleason E; Song J; Murphy SM; Ekema G; Doucette C; Hanniford D; Palmer M; Pawlowski G; Danzig J; Loftus M; Hunady K; Sherf B; Mays RW; Stricker-Krongrad A; Brunden KR; Bennani YL; Harrington JJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3287-90. PubMed ID: 20457519
[TBL] [Abstract][Full Text] [Related]
18. Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism.
Wang Y; Fu Z; Schmitt M; Wang X; Shen W; Rickel E; Martin T; Budelsky A; Marshall D; Collins T; Tang HL; Medina JC; Liu JJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):367-70. PubMed ID: 22119474
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin D₂ receptor CRTH2 antagonists for the treatment of inflammatory diseases.
Chen JJ; Budelsky AL
Prog Med Chem; 2011; 50():49-107. PubMed ID: 21315928
[No Abstract] [Full Text] [Related]
20. A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils.
Royer JF; Schratl P; Carrillo JJ; Jupp R; Barker J; Weyman-Jones C; Beri R; Sargent C; Schmidt JA; Lang-Loidolt D; Heinemann A
Eur J Clin Invest; 2008 Sep; 38(9):663-71. PubMed ID: 18837743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
